How is Prostate cancer diagnosed?

['Thikĩrĩria karatathi gaka']

Mũrimũ wa prostate ũtangĩthimwo mũndũ amenyaga atĩa atĩ arĩ na kansa?

Mũrimũ wa prostate ũtwaranaga na njĩra ya gũthimwo na njĩra ingĩ ta:

1. Ũthuthuria wa kamũberethi ya kũgemia: Ndagĩtarĩ ekagĩra kaara karĩa gakoragwo na maguta kamũberethi-inĩ ĩyo nĩguo athuthurie prostate one kana harĩ kĩndũ kĩũru.

2. Ũthuthuria wa Prostate-Specific Antigen (PSA): Ũyũ nĩ ũthuthuria wa thakame ũrĩa ũthimaga gĩthimi kĩa PSA, ĩrĩa nĩ proteini ĩthondekagwo nĩ prostate gland.

Kũingĩha kwa PSA no kuonanie atĩ mũndũ arĩ na kansa ya prostate.

3. Kĩgeranio kĩa Transrectal Ultrasound (TRUS): Kameme kanini nĩ kamwegagĩrũo thĩinĩ wa kanyua nĩguo koneke mũkiha wa prostate ũkĩhũthĩra mĩhũmũ ya mũgambo.

Ũndũ ũcio no ũteithie kũmenya mũrimũ o wothe wa prostate.

4. Kĩndũ kĩrutagwo thĩinĩ wa mũndũ: Gĩcunjĩ kĩnini kĩa prostate gĩkagerio na macini ya gũthima kĩndũ kĩnini mũno kĩonekaga (microscope) gĩkoneka kana harĩ na tũhengereta twa kansa.

Ĩyo noyo njĩra ĩrĩa tu ĩngĩtũma mũndũ amenye kana arĩ na kansa ya prostate.

5. Ũthuthuria wa Magnetic Resonance Imaging (MRI): Ũthuthuria wa MRI wa prostate no ũteithie kũmenya maũndũ marĩa mangĩkorũo matariĩ na ũtongoria ũrĩa ũngĩhũthĩrũo gũthima kĩĩga.

6. Ũthuthuria wa DNA: Mandagĩtarĩ amwe no mahũthĩre ũthuthuria wa DNA nĩguo mamenye kana mũndũ arĩ na kansa na mamũtongorie ũrĩa egũthuura kana nĩ ekũrigitwo.

7. Ũthuthuria wa mahĩndĩ: Mũndũ no athuthurie mahĩndĩ nĩguo one kana kansa nĩ ĩtambĩte nginya mahĩndĩ-inĩ.

8. Komputa ya tomography (CT): Komputa ya tomography no ĩhũthĩrũo kũrora kana kansa nĩ ĩtambĩte ĩgĩthiĩ ciĩga-inĩ ingĩ kana harĩ nyama.

Nĩ ũndũ wa bata kũmenya atĩ ti arũme othe arĩa marĩ na PSA nyingĩ kana moimĩrĩro moru ma DRE marĩ na kansa ya prostate, na ti arũme othe arĩa marĩ na kansa ya prostate mangĩkorũo na PSA nyingĩ.

Nĩ ũndũ ũcio, mũndũ agĩrĩirũo nĩ gũthima thakame nĩguo athime kana nĩ ndwaru.

Makĩria ma ũguo, itua rĩa gũthima mũndũ kĩĩga gĩake rĩtuagwo thutha wa gũthuthuria maũndũ macio na kũrora maũndũ marĩa mangĩmũingĩria ũgwati-inĩ na maũndũ marĩa angĩenda.

['Ũhoro wa kwambĩrĩria']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM: Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 2011, 21 (2): 195-205.

Marenco J, Kasivisvanathan V, Emberton M: New standards in prostate biopsy. Arch Esp Urol. 2019, 72 (2): 142-149.

Moradi M, Mousavi P, Abolmaesumi P: Computer-aided diagnosis of prostate cancer with emphasis on ultrasound-based approaches: a review. Ultrasound Med Biol. 2007, 33 (7): 1010-28.

Cuperlovic-Culf M, Belacel N, Davey M, Ouellette RJ: Multi-gene biomarker panel for reference free prostate cancer diagnosis: determination and independent validation. Biomarkers. 2010, 15 (8): 693-706.

McGrath SE, Michael A, Morgan R, Pandha H: EN2: a novel prostate cancer biomarker. Biomark Med. 2013, 7 (6): 893-901.

An Y, Chang W, Wang W, Wu H, Pu K, Wu A, Qin Z, Tao Y, Yue Z, Wang P, Wang Z: A novel tetrapeptide fluorescence sensor for early diagnosis of prostate cancer based on imaging Zn2+ in healthy versus cancerous cells. J Adv Res. 2020, 24 (): 363-370.

[Consensus of Chinese experts on the application of molecular imaging targeting prostate specific membrane antigen in prostate cancer patients]. Zhonghua Wai Ke Za Zhi. 2018, 56 (2): 91-94.

Zhong WD, He HC, Bi XC, Ou RB, Jiang SA, Liu LS: cDNA macroarray for analysis of gene expression profiles in prostate cancer. Chin Med J (Engl). 2006, 119 (7): 570-3.

['Ũkaana: thibitarĩ']

['Website ĩno ĩkoragwo ĩrĩ ya kũrutana na kũheana ũhoro tu na ti ya kũheana ũtaaro wa ũrigitani kana ũtungata wa kĩĩmwĩrĩ.']

['Ũhoro ũrĩa ũrĩ thĩinĩ wa broshua ĩyo ndwagĩrĩirũo kũhũthĩrũo gũthima kana kũrigita mũrimũ mũna, na arĩa marenda ũtaaro wa ũrigitani magĩrĩirũo gũcaria ũteithio wa ndagĩtarĩ.']

['No wone atĩ netiwaki ya neuron ĩrĩa ĩheanaga macokio ma ciũria icio, ndĩkoragwo na ũkinyanĩru mũno ũhoro-inĩ wĩgiĩ namba. Kwa ngerekano, mũigana wa andũ arĩa magwatĩtio mũrimũ mũna.']

['Hingo ciothe caria ũtaaro wa ndagĩtarĩ kana mũndũ ũngĩ wagĩrĩire ũgima-inĩ waku wa mwĩrĩ igũrũ rĩgiĩ mũrimũ. Ndũkaanahũthie ũtaaro wa ndagĩtarĩ kana ũcererũo kũũcaria nĩ ũndũ wa ũndũ ũthomete thĩinĩ wa website ĩno. Ũngĩkorũo ũrona ta wacemania na ũndũ mũhiũ, hũra thimũ 911 kana ũthiĩ thibitarĩ ya hakuhĩ na harĩa ũrĩ. Gũtirĩ ũrata wa ndagĩtarĩ na mũrwaru wonekaga nĩ ũndũ wa website ĩno kana kũhũthĩrũo kwayo. BioMedLib kana aruti ayo a wĩra, kana mũndũ ũngĩ wothe ũrutĩte wĩra thĩinĩ wa website ĩno, ndarĩ na ũira, wa ĩmwe kwa ĩmwe kana wa ĩmwe kwa ĩmwe, wĩgiĩ ũhoro ũrĩa ũheanĩtwo ho kana ũrĩa ũhũthĩrĩtwo.']

['Ũregani: wĩyathi wa kwandĩka']

['Watho wa Digital Millennium Copyright Act wa 1998, 17 U.S.C. § 512 (the DMCA) ũheanaga ũhoti wa ene a ihoto cia wandĩki arĩa metĩkĩtie atĩ ũhoro ũrĩa ũroneka intanetiinĩ nĩ ũtharĩtie ihooto ciao kũringana na watho wa U.S. wa ihoto cia wandĩki.']

['Ũngĩkorũo na wĩtĩkio atĩ ũhoro kana kĩndũ kĩna gĩtahingũrĩtwo ũhoro-inĩ wĩgiĩ website kana ũtungata witũ nĩ gĩgũthũkia ihooto ciaku, wee (kana mũndũ ũrĩa ũgũgũthondekera) no ũtũtũmĩre notithi ũkĩũria ũhoro kana kĩndũ kĩu kĩeherio, kana ũrigĩrĩrio ndũgacihũthĩre.']

["Marũa macio magĩrĩire gũtũmwo na njĩra ya kwandĩkwo na e-mail (rora ũhoro wa andirethi gĩcunjĩinĩ kĩa 'Maũndũ ma kwaranĩria')."]

['DMCA ĩbataraga atĩ notithi yaku ya kuuna ihooto cia wandĩki ĩkorwo na ũhoro ũyũ: (1) ũtaarĩria wa wĩra ũrĩa ũrĩ na ihooto cia wandĩki ũrĩa ũrarumwo; (2) ũtaarĩria wa ũhoro ũrĩa ũrarumwo na ũhoro mũiganu wa gũtũhotithia kũmenya kũrĩa ũhoro ũcio ũrĩ; (3) ũhoro waku wa kwaranĩria, hamwe na andirethi, namba ya thimũ na andirethi ya e-mail; (4) ndũmĩrĩri yaku atĩ wĩ na wĩtĩkio mwega atĩ ũhoro ũcio ũramenererio ndũrĩ na rũtha rwa mwene wa watho, kana mũrũgamĩrĩri, kana rwa watho o wothe; ']

['(5) nĩ mwandĩkanĩire, na nĩ mũkũheo mũkaana wa kũheenania, atĩ ũhoro ũrĩa ũrĩ kĩmenyithiainĩ kĩu nĩ wa ma na atĩ mũrĩ na ũhoti wa kũhingia ihooto iria mũreganĩte nacio;']

['na (6) kĩrore kĩa mwene kĩhoto kana kĩa mũndũ wĩtĩkĩritio gwĩtongoria handũ ha mwene kĩhoto.']

['Kwaga kwandĩka ũhoro ũcio wothe no gũtũme gũtangĩka gwaku kũhĩtũke.']

['Ũhoro wa Kwaranĩria']

['Tũma ndũmĩrĩri ya kũbucia kũgerera thimũ kana thimũ ya mohoro.']

How is prostate cancer diagnosed?

Prostate cancer is diagnosed through a combination of tests and procedures, which may include:

1. Digital Rectal Exam (DRE): A doctor inserts a gloved, lubricated finger into the rectum to feel the prostate for any abnormalities.

2. Prostate-Specific Antigen (PSA) Test: This is a blood test that measures the level of PSA, a protein produced by the prostate gland.

Elevated PSA levels may indicate the presence of prostate cancer.

3. Transrectal Ultrasound (TRUS): A small probe is inserted into the rectum to create an image of the prostate using sound waves.

This can help identify any abnormalities in the prostate gland.

4. Biopsy: A small sample of prostate tissue is removed and examined under a microscope for the presence of cancer cells.

This is the only definitive way to diagnose prostate cancer.

5. Magnetic Resonance Imaging (MRI): An MRI scan of the prostate can help identify any abnormalities and guide the biopsy procedure.

6. Genomic Testing: Some doctors may use genomic tests to help determine the aggressiveness of the cancer and guide treatment decisions.

7. Bone Scan: A bone scan may be performed to check if the cancer has spread to the bones.

8. Computed Tomography (CT) Scan: A CT scan may be used to check if the cancer has spread to other organs or tissues.

It is important to note that not all men with elevated PSA levels or abnormal DRE results will have prostate cancer, and not all prostate cancers will cause elevated PSA levels.

Therefore, a biopsy is necessary to confirm the diagnosis.

Additionally, the decision to undergo a biopsy is made after considering the results of these tests and the individual's risk factors and preferences.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.